These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16458434)

  • 1. Hormone refractory prostate cancer: Management and advances.
    Sonpavde G; Hutson TE; Berry WR
    Cancer Treat Rev; 2006 Apr; 32(2):90-100. PubMed ID: 16458434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New targeted therapies in hormone-refractory prostate cancer].
    Oudard S; Banu E; Scotte F; Beuzeboc P; Guyader C; Medioni J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F62-8. PubMed ID: 17845995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
    Fischel JL; Ciccolini J; Formento P; Ferrero JM; Milano G
    Anticancer Drugs; 2006 Aug; 17(7):807-13. PubMed ID: 16926630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
    Masson S; Bahl A
    BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone-refractory prostate cancer: a shifting paradigm in treatment.
    Gallagher E; Gapstur R
    Clin J Oncol Nurs; 2006 Apr; 10(2):233-40. PubMed ID: 16708706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for prostate cancer: the role of hormonal treatment.
    Shahani R; Fleshner NE; Zlotta AR
    Discov Med; 2007 Aug; 7(39):118-24. PubMed ID: 18093474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
    Daskivich TJ; Regan MM; Oh WK
    Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: The androgen receptor remains front and centre.
    Saylor PJ
    Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H; Garcia JA
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
    Bhandari MS; Petrylak DP; Hussain M
    Eur J Cancer; 2005 Apr; 41(6):941-53. PubMed ID: 15808960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.